Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20095307 | 0.93 | NAMPT (0.43) | NAMPTALDH1A1PDE4ALMNAMAPT | |
| SCHEMBL20095455 | 0.91 | NAMPT (0.41) | NAMPTALDH1A1LMNAMAPTHTT | |
| SCHEMBL30292608 | 0.91 | NAMPT (0.41) | NAMPTALDH1A1LMNAMAPTHTT | |
| SCHEMBL20095389 | 0.90 | NAMPT (0.43) | NAMPTALDH1A1PDE4ALMNAMAPT | |
| SCHEMBL20095436 | 0.82 | NAMPT (0.46) | NAMPTALDH1A1LMNAMAPTPRMT3 | |
| SCHEMBL20095473 | 0.81 | NAMPT (0.51) | NAMPTALDH1A1LMNAMAPTPRMT3 | |
| SCHEMBL20095298 | 0.80 | NAMPT (0.47) | NAMPTPDE4A | |
| SCHEMBL20095426 | 0.80 | NAMPT (0.47) | NAMPTPDE4A | |
| SCHEMBL21462020 | 0.79 | NAMPT (0.38) | NAMPTALDH1A1LMNAMAPTHTT | |
| SCHEMBL21461993 | 0.78 | KMT2A (0.44) | NAMPTALDH1A1MAPTHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NAPRT, NNMT | NAMPT 1/4885ALDH1A1 2101/4885PDE4A 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.